Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

Oncotarget - 1 Mar 2016

Lim Sun Min, Park Hyung Soon, Kim Sangwoo, Kim Sora, Ali Siraj M, Greenbowe Joel R, Yang In Seok, Kwon Nak-Jung, Lee Jae Lyun, Ryu Min-Hee, Ahn Jin-Hee, Lee Jeeyun, Lee Min Goo, Kim Hyo Song, Kim Hyunki, Kim Hye Ryun, Moon Yong Wha, Chung Hyun Cheol, Kim Joo-Hang, Kang Yoon-Koo, Cho Byoung Chul

Abstract excerpt

BACKGROUND: Given the modest responses to everolimus, a mTOR inhibitor, in multiple tumor types, there is a pressing need to identify predictive biomarkers for this drug. Using targeted ultra-deep sequencing, we aimed to explore genomic alterations that confer extreme sensitivity to everolimus. RESULTS: We collected formalin-fixed paraffin-embedded tumor/normal pairs from 39 patients (22 with exceptional clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Head and Neck Neoplasms

Share to Neurofibromin 1

Share to Sarcoma

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis Complex 1 Protein

Share to Tuberous Sclerosis Complex 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 26859683
DOI: 10.18632/oncotarget.7234
PMCID: PMC4891139

Genes

BAP1
FGFR4
MTOR
TSC1
TSC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.PMID 26859683Read ↗

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Semantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.Semantic proximity Read ↗

Genome Sequencing Identifies a Basis for Everolimus SensitivitySemantic proximity Read ↗

Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.Semantic proximity Read ↗

Multiple gene aberrations and breast cancer: lessons from super-responders.Semantic proximity Read ↗

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.Semantic proximity Read ↗

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.Semantic proximity Read ↗

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Semantic proximity Read ↗

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcomaSemantic proximity Read ↗

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.